A bioreactor to predict the efficacy of antifungal therapies

Fungal spores can cause fatal lung infections (such as pulmonary aspergillosis) in people with weakened immune systems. 

To test for new antifungal drugs, it is important to determine the right dose to cause an antifungal effect without causing harm to the patient. This research is typically performed in animals but can provide results that differ from humans.

In this video Professor William Hope, University of Liverpool, describes a bioreactor developed with NC3Rs funding which contains layers of human cells. This novel bioreacter model can be used to study pulmonary aspergillosis and understand the potential effect of new antifungal drugs. It is currently being used to develop a new antifungal compound, which is in Phase III clinical trials.

Professor Hope was one of twelve researchers highlighted in our 2013 Research Review, which can be viewed as an ebook or downloaded as a pdf on our website.

This video, along with three other case studies from our research review, can be viewed on our brand new YouTube channel.



Log in or register to post comments

Keep in touch